Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 706 to 720 of 1512 results for patients and public

  1. Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]

    Awaiting development Reference number: GID-TA11821 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Sibeprenlimab for treating IgA nephropathy [ID6604]

    Awaiting development Reference number: GID-TA11668 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]

    Awaiting development Reference number: GID-TA11846 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development Reference number: GID-TA11661 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040]

    Awaiting development Reference number: GID-TA11591 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]

    Awaiting development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Awaiting development Reference number: GID-TA11276 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Gantenerumab for treating early Alzheimer's disease [TSID10668]

    Awaiting development Reference number: GID-TA11072 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]

    Awaiting development Reference number: GID-TA11059 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]

    Awaiting development Reference number: GID-TA11283 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]

    Awaiting development Reference number: GID-TA10967 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]

    Awaiting development Reference number: GID-TA11393 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development